TENAX THERAPEUTICS, INC. Proceeds from Issuance of Warrants
TENAX THERAPEUTICS, INC. (TENX) reported Proceeds from Issuance of Warrants of $6.52 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2024-08-13
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2024-03-31 was $6.52M, a 53.05% decline year-over-year.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2023-06-30 was $68.25K.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for the quarter ending 2023-03-31 was $13.90M.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for fiscal 2022 was $7.93M, a 13.75% decline from fiscal 2021.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for fiscal 2021 was $9.19M.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for fiscal 2014 was -$233.04K, a 135.49% decline from fiscal 2013.
- TENAX THERAPEUTICS, INC. proceeds from issuance of warrants for fiscal 2013 was $656.53K, a 79.03% decline from fiscal 2012.
| Period end | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $6.52M 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $6.52M 10-Q · filed 2024-05-14 | |||
| 2023-06-30 | $68.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $13.96M 10-Q · filed 2024-08-13 | $13.96M derived: sum of 3 quarters · filed 2024-08-13 | |
| 2023-03-31 | $13.90M 10-Q · filed 2024-05-14 | $13.90M derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $7.93M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $7.93M 10-Q · filed 2022-11-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $9.19M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $9.19M 10-Q · filed 2022-11-10 | |||
| 2014-04-30 | -$233.04K 10-K · filed 2017-03-16 | |||
| 2013-04-30 | $656.53K 10-K · filed 2014-07-29 | |||
| 2012-04-30 | $3.13M 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |